Cargando…
Applying Modeling and Simulations for Rational Dose Selection of Novel Toll‐Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need
Dual toll‐like receptor (TLR) 7 and TLR8 inhibitor enpatoran is under investigation as a treatment for lupus and coronavirus disease 2019 (COVID‐19) pneumonia. Population pharmacokinetic/pharmacodynamic (PopPK/PD) model‐based simulations, using PK and PD (inhibition of ex vivo‐stimulated interleukin...
Autores principales: | Klopp‐Schulze, Lena, Shaw, Jamie V., Dong, Jennifer Q., Khandelwal, Akash, Vazquez‐Mateo, Cristina, Goteti, Kosalaram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540480/ https://www.ncbi.nlm.nih.gov/pubmed/35390178 http://dx.doi.org/10.1002/cpt.2606 |
Ejemplares similares
-
518. Model-informed Dose Selection of Dual Toll-like Receptor 7/8 Inhibitor Enpatoran (M5049) for the Treatment of COVID-19 Pneumonia
por: Klopp-Schulze, Lena, et al.
Publicado: (2021) -
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8
por: Port, Andreas, et al.
Publicado: (2021) -
Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations
por: Seurat, Jérémy, et al.
Publicado: (2020) -
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models
por: Pantoja, Kristyn, et al.
Publicado: (2022) -
Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1
por: Vugmeyster, Yulia, et al.
Publicado: (2020)